Arzneimittelwerk Warngau
AMW GmbH is a specialty pharmaceutical company focused on providing biologically degradable drug delivery systems for innovative and cost-effective therapies. With modern production facilities in Germany, they cover the entire pharmaceutical value chain. Their mission is to supply patients and partners with high-quality medicines and enable affordable therapies through their advanced drug delivery systems, including approved products Goserelin and Leuprorelin, distributed globally. The company is expanding its leadership and product portfolio, establishing strategic partnerships, and advancing regulatory approvals for its innovative drug delivery systems.
Industries
Nr. of Employees
medium (51-250)
Arzneimittelwerk Warngau
Birkerfeld 11, 83627 Warngau, Germany
Products
Biodegradable subcutaneous GnRH‑agonist implant (1‑ and 3‑month formats)
Biodegradable subcutaneous implant delivering a GnRH‑agonist with one‑ and three‑month sustained‑release formats; developed in specific dosages (reported 3.6 mg and 10.8 mg) and described as clinically equivalent to an originator depot product.
Biodegradable subcutaneous GnRH‑agonist implant (prefilled‑syringe with applicator)
Biodegradable implant supplied in a prefilled syringe format with an integrated applicator; conformity assessment by a notified body was reported for the device‑combination and applicator under relevant regulatory processes.
Transdermal buprenorphine patch
Transdermal patch formulation for delivery of buprenorphine listed among portfolio products.
Transdermal rivastigmine patch
Transdermal patch formulation for delivery of rivastigmine listed among portfolio products.
Generic contraceptive vaginal ring
Development of a generic vaginal ring contraceptive equivalent to an established market product, representing capability in generic device‑based contraceptive development.
Biodegradable subcutaneous GnRH‑agonist implant (1‑ and 3‑month formats)
Biodegradable subcutaneous implant delivering a GnRH‑agonist with one‑ and three‑month sustained‑release formats; developed in specific dosages (reported 3.6 mg and 10.8 mg) and described as clinically equivalent to an originator depot product.
Biodegradable subcutaneous GnRH‑agonist implant (prefilled‑syringe with applicator)
Biodegradable implant supplied in a prefilled syringe format with an integrated applicator; conformity assessment by a notified body was reported for the device‑combination and applicator under relevant regulatory processes.
Transdermal buprenorphine patch
Transdermal patch formulation for delivery of buprenorphine listed among portfolio products.
Transdermal rivastigmine patch
Transdermal patch formulation for delivery of rivastigmine listed among portfolio products.
Generic contraceptive vaginal ring
Development of a generic vaginal ring contraceptive equivalent to an established market product, representing capability in generic device‑based contraceptive development.
Services
Development services for drug‑delivery systems including formulation, prototype development and development support for commercialization.
Clinical‑ and commercial‑scale manufacturing of implantable and transdermal drug‑delivery products, including capacity for scale‑up and controlled‑environment production.
Support for technology collaborations, territorial licensing, technology transfer and exclusive supply agreements, including commercial negotiation and partner integration.
Quality systems support and lifecycle management for regulatory compliance and post‑market product maintenance throughout commercial supply.
Development services for drug‑delivery systems including formulation, prototype development and development support for commercialization.
Clinical‑ and commercial‑scale manufacturing of implantable and transdermal drug‑delivery products, including capacity for scale‑up and controlled‑environment production.
Support for technology collaborations, territorial licensing, technology transfer and exclusive supply agreements, including commercial negotiation and partner integration.
Quality systems support and lifecycle management for regulatory compliance and post‑market product maintenance throughout commercial supply.
Expertise Areas
- Drug delivery systems
- Sustained‑release implant therapeutics
- Transdermal and vaginal delivery
- Formulation development and optimisation
Key Technologies
- Extrusion‑based manufacturing
- Biodegradable polymer implant platforms
- Sustained‑release formulation technologies
- Transdermal patch systems
News & Updates
AMW and AdhexPharma have completed a strategic transfer for transdermal systems.
AMW announced a record turnover of €38.2 million for 2024, with operational profitability achieved for the second consecutive year.
In 2022, AMW achieved its first operational profitability, marking a significant milestone.
AMW and AdhexPharma have completed a strategic transfer for transdermal systems.
AMW announced a record turnover of €38.2 million for 2024, with operational profitability achieved for the second consecutive year.
In 2022, AMW achieved its first operational profitability, marking a significant milestone.